Floatz logo

All-P-Ambo-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methylcytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-P-Thioguanylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiouridylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-Pthiouridylyl-( 3'?5')-P-Thiothymidylyl-(3'?5')-P-Thiothymidylyl-(3'?5')-2'-Deoxy-5-Methyl-P-Thiocytidylyl-(3'?5')-Pthiothymidylyl-( 3'?5')-P-Thiothymidylyl-(3'?5')-2'-Deoxy-Pthioadenylyl-( 3'?5')-2'-Deoxy-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-Deoxy-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-Pthioadenylyl-( 3'?5')-2'-O-(2-Methoxyethyl)-5-Methylcytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyluridine

Alzheimer Disease

Explore 299 assets in Alzheimer Disease →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Biogen
Modality
nucleic_acid
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05399888CT.gov
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Alzheimer Disease

AssetSponsorPhaseRating
All-P-Ambo-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methylcytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-P-Thioguanylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiouridylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-Pthiouridylyl-( 3'?5')-P-Thiothymidylyl-(3'?5')-P-Thiothymidylyl-(3'?5')-2'-Deoxy-5-Methyl-P-Thiocytidylyl-(3'?5')-Pthiothymidylyl-( 3'?5')-P-Thiothymidylyl-(3'?5')-2'-Deoxy-Pthioadenylyl-( 3'?5')-2'-Deoxy-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-Deoxy-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-Pthioadenylyl-( 3'?5')-2'-O-(2-Methoxyethyl)-5-Methylcytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyluridine (this asset)BiogenP2CCC · 53
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINEAkiva MintzP4BBB
MemantineCarnot LaboratoriesP4BBB
EscitalopramNYU Langone HealthP4BBB
FlortaucipirEli RadiopharmaP4BBB
RivastigmineAnhui Provincial HospitalP4BBB
FlorbetabenNational Institute of Mental Health (NIMH)P4BBB
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)Anhui Provincial HospitalP4BBB
SertralineAstraZenecaP4BBB

+42 more in the Alzheimer Disease cohort

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. All-P-Ambo-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methylcytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-P-Thioguanylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiouridylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-Pthiouridylyl-( 3'?5')-P-Thiothymidylyl-(3'?5')-P-Thiothymidylyl-(3'?5')-2'-Deoxy-5-Methyl-P-Thiocytidylyl-(3'?5')-Pthiothymidylyl-( 3'?5')-P-Thiothymidylyl-(3'?5')-2'-Deoxy-Pthioadenylyl-( 3'?5')-2'-Deoxy-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-Deoxy-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-Pthioadenylyl-( 3'?5')-2'-O-(2-Methoxyethyl)-5-Methylcytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyl-P-Thiocytidylyl-(3'?5')-2'-O-(2-Methoxyethyl)-5-Methyluridine in Alzheimer Disease. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/all-p-ambo-2-o-2-methoxyethyl-5-methyl-p-thiocytidylyl-35-2-o-2-methoxyethyl-5-methylcytidylyl-35-2-o-2-methoxyethyl-p-thioguanylyl-35-2-o-2-methoxyethyl-5-methyl-p-thiouridylyl-35-2-o-2-methoxyethyl-5-methyl-pthiouridylyl-35-p-thiothymidylyl-35-p-thiothymidylyl-35-2-deoxy-5-methyl-p-thiocytidylyl-35-pthiothymidylyl-35-p-thiothymidylyl-35-2-deoxy-pthioadenylyl-35-2-deoxy-5-methyl-p-thiocytidylyl-35-2-deoxy-5-methyl-p-thiocytidylyl-35-2-o-2-methoxyethyl-pthioadenylyl-35-2-o-2-methoxyethyl-5-methylcytidylyl-35-2-o-2-methoxyethyl-5-methyl-p-thiocytidylyl-35-2-o-2-methoxyethyl-5-methyl-p-thiocytidylyl-35-2-o-2-methoxyethyl-5-methyluridine-alzheimer-disease

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →